Cargando…

Molecular Profile and Matched Targeted Therapy for Advanced Breast Cancer Patients

(1) Background: Precision oncology is opening new treatment opportunities for patients suffering from solid tumors. In the last two decades, the advent of CDK4/6 inhibitors, immunotherapy, and antibody–drug conjugates (ADC) improved survival outcomes for advanced or metastatic breast cancers (BC). N...

Descripción completa

Detalles Bibliográficos
Autores principales:	Falcone, Rosa, Lombardi, Pasquale, Filetti, Marco, Fabi, Alessandra, Altamura, Valeria, Scambia, Giovanni, Daniele, Gennaro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954949/ https://www.ncbi.nlm.nih.gov/pubmed/36826152 http://dx.doi.org/10.3390/curroncol30020191

Ejemplares similares

Clinical and mutational profile of AT-rich interaction domain 1A-mutated cancers
por: Falcone, Rosa, et al.
Publicado: (2023)

Overview of Trop-2 in Cancer: From Pre-Clinical Studies to Future Directions in Clinical Settings
por: Lombardi, Pasquale, et al.
Publicado: (2023)

Oncologic Drugs Approval in Europe for Solid Tumors: Overview of the Last 6 Years
por: Falcone, Rosa, et al.
Publicado: (2022)

Breast Cancer Drug Approvals Issued by EMA: A Review of Clinical Trials
por: Duranti, Simona, et al.
Publicado: (2021)

PI3K Inhibitors in Advanced Breast Cancer: The Past, The Present, New Challenges and Future Perspectives
por: Fuso, Paola, et al.
Publicado: (2022)

Oligometastatic Breast Cancer: How to Manage It?
por: Barberi, Vittoria, et al.
Publicado: (2021)

SUN-420 Spontaneous Changes in TSH Levels After Thyroidectomy During Long-Term Follow-Up
por: Grani, Giorgio, et al.
Publicado: (2020)

Anti epidermal growth factor receptor therapy in small bowel adenocarcinoma: Case report and literature review
por: Falcone, Rosa, et al.
Publicado: (2018)

Cancer Care During COVID-19 Era: The Quality of Life of Patients With Thyroid Malignancies
por: Falcone, Rosa, et al.
Publicado: (2020)

Adjuvant Treatment Recommendations in Early-Stage Endometrial Cancer: What Changes With the Introduction of The Integrated Molecular-Based Risk Assessment
por: Nero, Camilla, et al.
Publicado: (2021)

Updated Neoadjuvant Treatment Landscape for Early Triple Negative Breast Cancer: Immunotherapy, Potential Predictive Biomarkers, and Novel Agents
por: Garufi, Giovanna, et al.
Publicado: (2022)

Molecular profiling of advanced solid tumours. The impact of experimental molecular-matched therapies on cancer patient outcomes in early-phase trials: the MAST study
por: Gambardella, Valentina, et al.
Publicado: (2021)

Economic Evaluation for Palbociclib Plus Fulvestrant vs Ribociclib Plus Fulvestrant and Abemaciclib Plus Fulvestrant in Endocrine-Resistant Advanced or Metastatic Breast Cancer in Italy
por: Colombo, Giorgio Lorenzo, et al.
Publicado: (2023)

The likelihood of being helped or harmed as a patient-centred tool to assess cyclin dependent kinase 4/6 inhibitors clinical impact and safety in metastatic breast cancer: a systematic review and sensitivity-analysis
por: Mastrantoni, Luca, et al.
Publicado: (2023)

Sonographic Risk Stratification Systems for Thyroid Nodules as Rule-Out Tests in Older Adults
por: Grani, Giorgio, et al.
Publicado: (2020)

Transcriptome of Male Breast Cancer Matched with Germline Profiling Reveals Novel Molecular Subtypes with Possible Clinical Relevance
por: Zelli, Veronica, et al.
Publicado: (2021)

Advanced Microscopy Techniques for Molecular Biophysics
por: Barsanti, Laura, et al.
Publicado: (2023)

Integration of PARP-inhibitors in ovarian cancer therapy
por: Pietragalla, Antonella, et al.
Publicado: (2020)

Identification of Thyroid-Associated Serum microRNA Profiles and Their Potential Use in Thyroid Cancer Follow-Up
por: Rosignolo, Francesca, et al.
Publicado: (2017)

Liquid biopsy identifies actionable dynamic predictors of resistance to Trastuzumab Emtansine (T-DM1) in advanced HER2-positive breast cancer
por: Allegretti, Matteo, et al.
Publicado: (2021)

Palbociclib Plus Fulvestrant or Everolimus Plus Exemestane for Pretreated Advanced Breast Cancer with Lobular Histotype in ER+/HER2− Patients: A Propensity Score-Matched Analysis of a Multicenter Retrospective Patient Series †
por: Orlandi, Armando, et al.
Publicado: (2020)

Unusual phylogenetic tree and circulating actionable ESR1 mutations in an aggressive luminal/HER2-low breast cancer: Case report
por: Allegretti, Matteo, et al.
Publicado: (2023)

Treating advanced breast cancer with metronomic chemotherapy: what is known, what is new and what is the future?
por: Cazzaniga, Marina Elena, et al.
Publicado: (2019)

Novel directions in molecular systems design: The case of light-transducing synthetic cells
por: Stano, Pasquale, et al.
Publicado: (2017)

Molecular profiles of BRCA1-mutated and matched sporadic breast tumours: relation with clinico-pathological features
por: Berns, E M J J, et al.
Publicado: (2001)

Changing molecular profile of brain metastases compared with matched breast primary cancers and impact on clinical outcomes
por: Thomson, A H, et al.
Publicado: (2016)

Loss of Function SETD2 Mutations in Poorly Differentiated Metastases from Two Hürthle Cell Carcinomas of the Thyroid
por: Pecce, Valeria, et al.
Publicado: (2020)

Role of Immune Checkpoint Inhibitors in Cervical Cancer: From Preclinical to Clinical Data
por: Duranti, Simona, et al.
Publicado: (2021)

Assessing the pathogenicity of BRCA1/2 variants of unknown significance: Relevance and challenges for breast cancer precision medicine
por: De Paolis, Elisa, et al.
Publicado: (2023)

Clinical, Radiometabolic and Immunologic Effects of Olaparib in Locally Advanced Triple Negative Breast Cancer: The OLTRE Window of Opportunity Trial
por: Schettini, Francesco, et al.
Publicado: (2021)

Matching Mechanics and Energetics of Muscle Contraction Suggests Unconventional Chemomechanical Coupling during the Actin–Myosin Interaction
por: Pertici, Irene, et al.
Publicado: (2023)

Lie groups, differential equations, and geometry: advances and surveys
por: Falcone, Giovanni
Publicado: (2017)

Development of a Digital Research Assistant for the Management of Patients’ Enrollment in Oncology Clinical Trials within a Research Hospital
por: Cesario, Alfredo, et al.
Publicado: (2021)

Targeted Biomarker Profiling of Matched Primary and Metastatic Estrogen Receptor Positive Breast Cancers
por: Schleifman, Erica B., et al.
Publicado: (2014)

RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives
por: Infante, Marco, et al.
Publicado: (2019)

Ovarian Reserve after Chemotherapy in Breast Cancer: A Systematic Review and Meta-Analysis
por: Romito, Alessia, et al.
Publicado: (2021)

Computational reactive–diffusive modeling for stratification and prognosis determination of patients with breast cancer receiving Olaparib
por: Schettini, Francesco, et al.
Publicado: (2023)

Patient-derived organoids and high grade serous ovarian cancer: from disease modeling to personalized medicine
por: Nero, Camilla, et al.
Publicado: (2021)

Advances in Early Breast Cancer Risk Profiling: From Histopathology to Molecular Technologies
por: Pescia, Carlo, et al.
Publicado: (2023)

Anti-EGFR monoclonal antibody Cetuximab displays potential anti-cancer activities in feline oral squamous cell carcinoma cell lines
por: Altamura, Gennaro, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qolqfka82rjkqja2tgc5n434sb